RxDoctor Payments Data

John Unison, MD

Internal Medicine · Plainfield, INNPI 1972598951

Payments from drug & device makers

$1,008in general payments, 2019–2025

Across 91 payments — averaging $11.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$314
  • Novo Nordisk$134
  • AbbVie$114
  • Amgen$61
  • AstraZeneca$54
  • Novartis$43
  • plus $288 from 14 others

What the payments were for

  • Food & beverage$98898%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,008 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$104,565
Medicare patients
316
Services billed
1,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin138$156,472
MounjaroTirzepatide97$126,149
OzempicSemaglutide54$88,387
EliquisApixaban56$52,580
RybelsusSemaglutide22$41,553
JanuviaSitagliptin Phosphate23$35,225
MyrbetriqMirabegron63$34,435
TrulicityDulaglutide25$34,151
XareltoRivaroxaban30$32,119
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$31,876
Bydureon BciseExenatide Microspheres24$29,279
TradjentaLinagliptin29$28,319
LinzessLinaclotide28$23,205
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$15,547
Breo ElliptaFluticasone/Vilanterol31$13,943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$314$160,300122 claims
Novo NordiskOzempic, Rybelsus$134$129,94076 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$26$61,36680 claims
PfizerEliquis$11$52,58056 claims
Johnson & JohnsonXarelto$11$32,11930 claims
AbbVieLinzess, Synthroid$114$31,238138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Plainfield

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →